When used fittingly, REMS can ensure safe use of prescribed drugs. However, applying REMS to oncology and supportive-care drugs must be done carefully.
Jessica DeMartino, PhD
Advertisement
Articles by Jessica DeMartino, PhD
The management of risk in medicine is emerging as a priority topic for numerous stakeholders, including patients, providers (physicians, other prescribers, and pharmacists), specialty pharmacies, industry, and government organizations.
Advertisement
Latest Updated Articles
Impact of Risk Evaluation and Mitigation Strategies in OncologyOctober 21st 2011
- Impact of Risk Evaluation and Mitigation Strategies in Oncology
December 21st 2010
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Factors Associated With GLP-1 RA Nonresponse in T2D—and What Pharmacists Should Screen For
2
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk
3
ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says
4
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
5